Pyrazine

Pyrazine

SCHEMBL14840433

Cc1ccccn1.c1cnccn1

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
HSP90AA1 P07900 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GRM5 P41594 1/20 0.45
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
CCR8 P51685 1/20 0.43
METAP1 P53582 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
DOHH Q9BU89 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
NOS3 P29474 2/20 0.41
NOS1 P29475 2/20 0.41
NOS2 P35228 2/20 0.41
CYP2A6 P11509 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL5499506 0.92 TDP1 (0.45) NPC1HSP90AA1L3MBTL1GRM5KDM4E
SCHEMBL29599136 0.92 KDM4E (0.50) NPC1HSP90AA1L3MBTL1GRM5KDM4E
SCHEMBL29472848 0.92
SCHEMBL16322907 0.92 KDM4E (0.50) NPC1HSP90AA1L3MBTL1GRM5KDM4E
SCHEMBL4733426 0.92 KDM4E (0.50) NPC1HSP90AA1L3MBTL1GRM5KDM4E
SCHEMBL2684 0.92
SCHEMBL16472174 0.90 TSHR (0.43) NPC1HSP90AA1L3MBTL1GRM5KDM4E
Pyridine SCHEMBL29291035 0.90 NPC1 (0.43) NPC1HSP90AA1L3MBTL1GRM5KDM4E
SCHEMBL25382981 0.89
Hydrochloric Acid SCHEMBL21723652 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US claimed
US-20130090334-A1 AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS Hoffmann-La Roche Inc (US) 2013-04-11 US claimed
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2013-04-11 US disclosed
WO-2013050341-A1 AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-04-11 WO disclosed
WO-2013050270-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2013-04-11 WO disclosed
US-20130090334-A1 AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS Hoffmann-La Roche Inc (US) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090333-A1 BENZOXAZINE DERIVATIVES AS CRAC MODULATORS RYR2, CACNA1E, RYR1 NPC1 1352/4885HSP90AA1 2765/4885L3MBTL1 4783/4885
US-20130090334-A1 AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS ORAI1, CACNA1E, RYR2 NPC1 2484/4885HSP90AA1 3095/4885L3MBTL1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.